Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus DOXY 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus DOXY 100.
DECLOMYCIN vs DOXY 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic